Pemphigus vulgaris (PV) belongs to the group of autoimmune blistering diseases. PV can affect not only mucous membranes, but also the skin and it is characterized by serum IgG autoantibodies against desmoglein 1 and 3, two major components of desmosomes. The introduction of glucocorticoids improved dramatically the prognosis of patients affected by PV. However, long-term use of high dose corticosteroids and adjuvant steroid-sparing immunosuppressants can lead to several adverse events. Rituximab, a chimeric anti-CD20 monoclonal antibody, has been recently approved as in-label therapy for PV, leading to an improvement of the prognosis and higher remission rate. Furthermore, other anti B-cell therapies and several anti-CD20 biosimilars have been introduced in the clinical practice. We focused on present and future therapeutic approaches in PV.

Pemphigus Vulgaris: Present and Future Therapeutic Strategies / Didona, D; Paolino, G; Di Zenzo, G; Didona, B; Pampena, R; Di Nicola, Mr; Mercuri, Sr. - In: DERMATOLOGY PRACTICAL & CONCEPTUAL. - ISSN 2160-9381. - (2022).

Pemphigus Vulgaris: Present and Future Therapeutic Strategies

Paolino G;Di Zenzo G;Pampena R;
2022

Abstract

Pemphigus vulgaris (PV) belongs to the group of autoimmune blistering diseases. PV can affect not only mucous membranes, but also the skin and it is characterized by serum IgG autoantibodies against desmoglein 1 and 3, two major components of desmosomes. The introduction of glucocorticoids improved dramatically the prognosis of patients affected by PV. However, long-term use of high dose corticosteroids and adjuvant steroid-sparing immunosuppressants can lead to several adverse events. Rituximab, a chimeric anti-CD20 monoclonal antibody, has been recently approved as in-label therapy for PV, leading to an improvement of the prognosis and higher remission rate. Furthermore, other anti B-cell therapies and several anti-CD20 biosimilars have been introduced in the clinical practice. We focused on present and future therapeutic approaches in PV.
anti-CD20 antibodies; neonatal Fc receptor (FcRn); pemphigus; rituximab; treatment.
01 Pubblicazione su rivista::01a Articolo in rivista
Pemphigus Vulgaris: Present and Future Therapeutic Strategies / Didona, D; Paolino, G; Di Zenzo, G; Didona, B; Pampena, R; Di Nicola, Mr; Mercuri, Sr. - In: DERMATOLOGY PRACTICAL & CONCEPTUAL. - ISSN 2160-9381. - (2022).
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1630568
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 4
  • ???jsp.display-item.citation.isi??? ND
social impact